axomadol

Small moleculeexperimental

Axomadol is a synthetic, centrally-acting opioid analgesic related to tramadol which was under investigation by Endo Pharmaceuticals in collaboration with Grünenthal GmbH for the treatment of chronic, moderate to severe lower back pain and arthrosis. Development was halted after phase II clinical trials as it did not meet the pre-determined clinical endpoints. — Wikipedia

Clinical trial activity

4 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Dec 30, 2004 (NCT03761407)

Timeline

2000s

Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Jan 1, 2009
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Delta opioid receptorAGONIST
OPRD1 agonist
Haven't found any references that mentioned activity at targets
- Delta-type opioid receptor (OPRD1) ↗
Kappa opioid receptorAGONIST
OPRK1 agonist
Haven't found any references that mentioned activity at targets
- Kappa-type opioid receptor (OPRK1) ↗
Mu opioid receptorAGONIST
OPRM agonist
Haven't found any references that mentioned activity at targets
- Mu-type opioid receptor (OPRM) ↗

Chemistry & pharmacology

Loading structure…

SMILES

COc1cccc(C2(O)CC(O)CCC2CN(C)C)c1

Mol. weight: 279.38 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

axomadol
axomadol
axomadol
bn110 base
bn110 base
en-3324
en-3324
grt-0151y
grt-0151y
grt151 base
grt151 base

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01043263	Phase 2	Dec 1, 2009	Grunenthal
NCT03768024	Phase 1	Jun 21, 2007	Grunenthal
NCT03765658	Phase 1	Jan 20, 2006	Grunenthal
NCT03761407	Phase 1	Dec 30, 2004	Grunenthal

Showing 4 of 4 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Grunenthal	For profit	4	4	2	2004

1 organizations

Page 1 / 1